MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo

Figure 4

MEK inhibitors diminish organoid formation and eliminate CTCs in vivo. (a) Representative micrograph of RFP+ organoid cultures (left, 5493 cells). Organoid formation under treatment with PD0325901 (PD) (middle) and trametinib (Tra) (right) in 3 primary cell lines treated as indicated. (b) Viability of preformed organoids with PD0325901 treatment in vitro. (c) Absolute numbers of circulating tumor cells (CTCs) in CKP mice treated with either vehicle control or refametinib as described in [15]. for all experiments. vs. control.

(a)

(b)

(c)